Friday, March 19, 2010: 12:30 PM-2:00 PM
Grand Hall (Hyatt Regency Atlanta)
Poster
123
To Pet or Not: Canine Assisted Therapy and the Risk of Clostridium difficile
Anne Rizzo, MD, Inova Fairfax Hospital;
Leslie Horton, RN, Inova Fairfax Hospital;
Robyn Richmond, MD, Inova Fairfax Hospital;
Christine Burke, Inova Fairfax Hospital;
Keilla Schmidt, MD, Inova Fairfax Hospital;
Yung-Fu Chang, DVM, PhD, Cornell University;
Tayseer Aldaghlas, MD, Inova Fairfax Hospital
124
Fluoroquinolone Use is a Specific Risk Factor for Clostridium difficile Infection due to the Highly Fluoroquinolone Resistant Epidemic Strain BI/NAP1
Jeffrey T. Wieczorkiewicz, PharmD, Midwestern University;
Bert K. Lopansri, MD, Hines VA Hospital and Loyola University Medical Center;
Alexander Tomich, RN, MSN, Hines VA Hospital and Loyola University Medical Center;
Walter E. Zurkowski, BS, Hines VA Hospital and Loyola University Medical Center;
Susan P. Sambol, BD, Hines VA Hospital and Loyola University Medical Center;
Dale N. Gerding, MD, Hines VA Hospital and Loyola University Medical Center;
Stuart Johnson, MD, Hines VA Hospital and Loyola University Medical Center
125
A Quick C. difficile Infection “Intervention”: Change in Toxin Assay Results in Lower Number of CDI Cases with No Changes in Patient Outcomes
Kathleen McMullen, MPH, CIC, Barnes Jewish Hospital;
Anthony J. Russo, MPH, Barnes Jewish Hospital;
Susan M. Copper, MT(ASCP), Barnes Jewish Hospital;
David Warren, MD, Washington University School of Medicine;
Erik R. Dubberke, MD, MSPH, Washington University School of Medicine
126
Acquisition of Clostridium difficile Colonization and Infection in a Department of Veterans Affairs Long-Term Care Facility
Suresh Ponnada, M.D., Louis Stokes Cleveland VA Medical Center;
Dubert Guerrero, MD, University Hospitals of Cleveland/Case Med. Ctr.;
Lucy Jury, N.P., Louis Stokes Cleveland VA Medical Center;
Michelle Nerandzic, BS, Louis Stokes Cleveland VA Medical Center;
Jen Cadnum, Louis Stokes Cleveland VA Medical Center;
Curtis J. Donskey, Cleveland VA Medical Center
128
Development of a ‘snapshot' PCR ribotyping scheme within the National Surveillance Program for C. difficile Infection (CDI) in Scotland
Camilla Wiuff, PhD, Health Protection Scotland;
Derek J. Brown, BSc(Hons), Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory;
Henry Mather, Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory;
A-Lan Banks, Health Protection Scotland;
Anne Eastaway, Health Protection Scotland;
John E. Coia, Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory
129
Antigen Based Assays Show Decreased Sensitivity for Several Clostridium difficile Ribotypes Including the Epidemic 027 Strain
Fred C. Tenover, Ph.D., Cepheid;
Susan Novak-Weekley, PhD, SCPMG Regional Reference Laboratory;
Thomas Akerlund, PhD, Swedish Institute for Infectious Diseases;
Ferric Fang, MD, University of Washington School of Medicine;
Alice S. Weissfeld, PhD, Microbiology Specialists Inc;
Thomas Davis, MD., PhD, Wishard Memorial Hospital;
Lance R. Peterson, MD, NorthShore University HealthSystem;
Christopher Woods, MD, Durham Veterans Affairs Medical Center;
Paul Schreckenberger, PhD, Loyola University Medical Center;
Beth Marlowe, PhD, SCPMG Regional Reference Laboratory;
Ellen Jo Baron, PhD, Cepheid;
David H. Persing, MD, PhD, Cepheid
133
High Doses of Oral Vancomycin Are Associated with Increased Fecal Levels in Patients with Suspected Clostridium Difficile Infection
Milagros Gonzales, B.Sc, Université de Sherbrooke;
Jacques Pepin, MD, Université de Sherbrooke;
Eric Frost, Ph.D, Université de Sherbrooke;
Julie Carrier, MD, Université de Sherbrooke;
Patrice Lamarre, BPharm, Université de Sherbrooke;
Louis Valiquette, MD, Université de Sherbrooke
137
Risk Factors and Molecular Analysis of Clostridium difficile Infection in Hospitalized Adults
Eric Kajioka, MD, University of Colorado School of Medicine;
Mary Bessesen, Department of Veterans Affairs Medical Center-Denver;
Allison Sabel, MD, PhD, Denver Health Medical Center;
Timothy C. Jenkins, MD, Denver Health Medical Center;
Connie S. Price, MD, Denver Health Medical Center
138
Countywide Hospital Risks of Clostridium difficile Infection (CDI) and the Impact of Including Post-Discharge Events
Courtney Reynolds, MS, School of Social Ecology and Health Policy Research Institute, University of California Irvine School of Medicine;
Taliser R. Avery, BS, Harvard Medical School and Harvard Pilgrim Health Care Institute;
Erik R. Dubberke, MD, MSPH, Department of Medicine, Washington University School of Medicine;
Susan S. Huang, MD, MPH, Division of Infectious Diseases and Health Policy Research Institute, University of California Irvine School of Medicine
140
Comparison of Three Enzyme Immunoassays for the Detection of Clostridium difficile
J. Ian Stuart, MD, London Health Sciences Centre;
Sue Milburn, London Health Sciences Centre;
Lisa Schoffer, London Health Sciences Centre;
Jenny Profota, London Health Sciences Centre;
Romina C. Reyes, London Health Sciences Centre;
Michael A. John, London Health Sciences Centre;
Robert Lannigan, London Health Sciences Centre;
Zafar Hussain, London Health Sciences Centre
142
A Targeted Strategy to Wipe Out C. difficile
Robert Orenstein, D.O., Mayo Clinic-Minnesota;
James McManus, Mayo Clinic-Minnesota;
Leslie Fedraw, Mayo Clinic-Minnesota;
Linda Grupa RN, MPH, Mayo Clinic-Minnesota;
Kimberly C. Aronhalt RN, Mayo Clinic-Minnesota;
Laurie A. Czaplewski RN, Mayo Clinic-Minnesota;
Michelle Hedin RN, Mayo Clinic-Minnesota;
Lynn Johnson, RN, Mayo Clinic-Minnesota;
Kristin D. Negley RN, Mayo Clinic-Minnesota;
Amy M. Zwygart RN, Mayo Clinic-Minnesota;
Conor G. Loftus, MD, Mayo Clinic-Minnesota
143
Clostridium difficile-associated disease – a newly notifiable disease in Ireland
Fiona Roche, PhD, Health Protection Surveillance Centre;
Sheila Donlon, RGN, Health Protection Surveillance Centre;
Paul McKeown, MB, Health Protection Surveillance Centre;
Darina O'Flanagan, MB, Health Protection Surveillance Centre;
Fidelma Fitzpatrick, MD, Health Protection Surveillance Centre
145
Effectiveness of Microfiber Cloths in Reducing Clostridium difficile (CD) from the Patient Environment
Christine E. Hendrickson, RN, BSHA, CIC, University of Minnesota Medical Center, Fairview;
Andrew Streifel, University of Minnesota;
Mark Gallivan, BS, University of Minnesota;
Teresa Rakoczy, University of Minnesota Medical Center, Fairview;
Susan Kline, MD, Univ of Minnesota;
Douglas Green, University of Minnesota Medical Center, Fairview
146
Efficacy of a Targeted Bleach Cleaning Intervention to Reduce the Incidence of Endemic Clostridium difficile-Associated Diarrhea in a Multi-Hospital Healthcare System
Sanaz Abderrahmane, MD, Good Samaritan Hospital;
Stephen Blatt, MD, I D Consultants of Ohio;
Jenni Steinbrunner, BS, Good Samaritan Hospital;
Lyn Plummer, RN, CIC, Bethesda North Hospital;
Ann Halverstadt, RN, BSN, Good Samaritan Hospital;
Toni Kamp, RN, CIC, Good Samaritan Hospital;
Tom Imhoff, Pharm, D, Good Samaritan Hospital;
Rakesh Shukla, PhD, University of Cincinnati;
Shu Zheng, MS, University of Cincinnati
147
Identification of a Pseudo-Outbreak of C. difficile Infection (CDI): Importance of Evaluating Test Performance
Natasha Bagdasarian, MD, MPH, University of Michigan;
Benrong Chen, MS, PhD, University of Michigan;
Christopher Harrison, MPH, University of Michigan;
William LeBar, MS, University of Michigan;
Duane Newton, PhD, University of Michigan;
Neeharika Kalakota, University of Michigan;
Laraine Washer, MD, University of Michigan;
Carol Chenoweth, MD, University of Michigan
149
Comparison of Risk factors and Outcomes of Community-Onset (CO) and Hospital-Onset (HO) Clostridium difficile infection (CDI) in the Elderly-A Case-Control Study
Teena Chopra, MD, Detroit Medical Center,Wayne State University;
Jatinder Hothi, MD, Detroit Medical Center,Wayne State University;
Luigino Bernabela, MD, Detroit Medical Center,Wayne State University;
Ahmad Mohammadieh, BS, Detroit Medical Center,Wayne State University;
Keith S. Kaye, MD, MPH, Detroit Medical Center,Wayne State University;
George Alangaden, MD, Detroit Medical Center,Wayne State University
150
High Proportion of False-Positive C. difficile (CD) ELISA Toxin Assays in Pediatric Patients
Philip Toltzis, MD, Rainbow Babies and Children's;
Michelle Nerandzic, BS, Louis Stokes Cleveland VA Medical Center;
Elie Saade, MD, Louis Stokes Cleveland VA Medical Center;
Maryanne O'Riordan, MS, Rainbow Babies and Children's;
Sarah Smathers, MPH, Children's Hospital of Philadelphia;
Theoklis Zaoutis, MD, Children's Hospital of Philadelphia;
Jason Kim, MD, Children's Hospital of Philadelphia;
Curtis Donskey, Louis Stokes Cleveland VA Medical Center
152
Surveillance of Clostridium difficile in Wales
Mari Morgan, Welsh Healthcare Associated Infection Programme, Public Health Wales NHS Trust;
Anthony Harris, MD, MPH, University of Maryland School of Medicine;
Victoria McClure, Welsh Healthcare Associated Infection Programme, Public Health Wales NHS Trust;
Michael Roberts, Informatics, Public Health Wales NHS Trust;
D. Nicholas Looker, NPHS Microbiology Rhyl, Public Health Wales NHS Trust;
Eleri Davies, Welsh Healthcare Associated Infection Programme, Public Health Wales NHS Trust
153
Failure of fecal toxin A/B to reliably detect Clostridium difficile in immunocompromised patients: Toxigenic cultures as new gold standard
Andreas F. Widmer, MD, MS, University Hospital Basel;
Anne M. Strandén, PhD, University Hospital Basel;
Gregory Mansella, MD, University Hospital Basel;
Marc Dangel, MPH, University Hospital Basel;
Lukas Fenner, MD, MIH, University of Bern;
Reno Frei, MD, University Hospital Basel
154
Clostridium difficile associated diarrhea at a tertiary care center in lebanon
Nisreen Sidani, MSN, American University of Beirut Medical Center;
Zeina Knio, American University of Beirut Medical Center;
Nada Zahreddine, American University of Beirut Medical Center;
Souha Kanj Sharara, American University of Beirut Medical Center;
George Araj, American University of Beirut Medical Center;
Zeina Kanafani, American University of Beirut Medical Center
155
: Impact of a Change in Testing Method for Clostridium difficile Infection (CDI) on Rate of Diagnosis, Physician Practices and Costs
Trevor Van Schooneveld, MD, University of Nebraska Medical Center;
Benjamin H. Hinrichs, BA, University of Nebraska Medical Center;
Elizabeth D. Hermsen, PharmD, MBA, The Nebraska Medical Center;
Teresa Fitzgerald, The Nebraska Medical Center;
Mark Rupp, MD, University of Nebraska Medical Center
157
Investigation of the Molecular Epidemiology of Clostridium difficile in Scotland by MLVA
Derek J. Brown, BSc(Hons), Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory;
Camilla Wiuff, PhD, Health Protection Scotland;
Edwin Yip, BSc(Hons), Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory;
Gillian R. Douce, PhD, Glasgow Biomedical Research Centre;
Henry Mather, MSc, Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory;
Anne Eastaway, MD, Health Protection Scotland;
A-Lan Banks, BSc, Health Protection Scotland;
John E. Coia, PhD, Scottish Salmonella, Shigella & Clostridium difficile Reference Laboratory
159
Clostridium difficile (CD) One step closer to lower CD hospital-acquired infection (HAI) rates
Lynette Smith, RN, MSN, CIC, University of Pittsburgh Medical Center;
Cheryl McNally, MT, ASCP, University of Pittsburgh Medical Center;
Sam Krautz, BA, University of Pittsburgh Medical Center;
Carlene A. Muto, MD, MS, University of Pittsburgh Medical Center
161
Comparison of Enzyme Immunoassay (EIA), Glutamate Dehydrogenase (GDH), and Cytotoxin Assays to Toxigenic Culture for the Detection of Clostridium difficile in Stool Samples
Parul A. Patel, NorthShore University HealthSystem;
Payal P. Nagwekar, NorthShore University HealthSystem;
Maureen A. Harazin, NorthShore University HealthSystem;
Donna M. Hacek, NorthShore University HealthSystem;
Richard B. Thomson, PhD, NorthShore University HealthSystem;
Lance R. Peterson, MD, NorthShore University HealthSystem
![[ Visit the Fifth Decennial online ]](images/banner.gif)